Dilated cardiomyopathy: a pharmacotherapeutic research

ABSTRACT

Background: AHA defines cardiomyopathies as a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently are genetic.Methods: This is a prospective observational study conducted in the year 2017 at an OPD of Cardiology of a private hospital located in Telangana state, India. Data has been collected after diagnosis is made and treatment regimen is given by an Interventional Cardiologist.Results: Data has been collected from 78 cardiac patients, out of which 17.9% patients had Dilated Cardiomyopathy (DCM) among them 57.14% were male. In the present study DCM was reported more in the age group of 61-70 years (42.85%). Treatment pattern in most of the prescriptions include Diuretics, Beta blockers, Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARBs), Cardiac Glycosides, Antiplatelet and Antihyperlipidaemics.Conclusions: To conclude, lack of awareness among people about this disease is leading it to progress to advanced stages and prognosis of which is poor. Conducting community awareness programs can play a key component in improving the prognosis of this disease.